HB Wealth Management LLC Has $983,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

HB Wealth Management LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 23.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,119 shares of the biopharmaceutical company’s stock after acquiring an additional 212 shares during the period. HB Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $983,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of REGN. Premier Path Wealth Partners LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $453,000. GPS Wealth Strategies Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 15.8% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the biopharmaceutical company’s stock valued at $451,000 after purchasing an additional 70 shares during the period. Clearview Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 13 shares during the period. Oak Harvest Investment Services lifted its position in shares of Regeneron Pharmaceuticals by 25.6% in the fourth quarter. Oak Harvest Investment Services now owns 1,211 shares of the biopharmaceutical company’s stock valued at $1,064,000 after buying an additional 247 shares during the last quarter. Finally, Everhart Financial Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 5.9% in the fourth quarter. Everhart Financial Group Inc. now owns 411 shares of the biopharmaceutical company’s stock valued at $361,000 after purchasing an additional 23 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, SVP Christopher R. Fenimore sold 2,448 shares of the business’s stock in a transaction dated Wednesday, December 27th. The stock was sold at an average price of $856.71, for a total value of $2,097,226.08. Following the completion of the sale, the senior vice president now directly owns 14,372 shares of the company’s stock, valued at approximately $12,312,636.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 2,049 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $898.00, for a total transaction of $1,840,002.00. Following the transaction, the director now directly owns 1,247 shares of the company’s stock, valued at approximately $1,119,806. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Christopher R. Fenimore sold 2,448 shares of the stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $856.71, for a total transaction of $2,097,226.08. Following the completion of the sale, the senior vice president now owns 14,372 shares of the company’s stock, valued at approximately $12,312,636.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,226 shares of company stock valued at $17,061,869. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:REGN opened at $961.09 on Tuesday. The business has a fifty day simple moving average of $956.46 and a 200 day simple moving average of $877.04. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The firm has a market cap of $105.49 billion, a P/E ratio of 27.66, a P/E/G ratio of 2.78 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the previous year, the company earned $10.96 EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.75 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 6th. Barclays raised their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 6th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Finally, Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $935.00 to $937.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $963.50.

Get Our Latest Analysis on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.